GlassScriptPhysician profile
Atif Ghaffar
NPI 1679159107
$4,052.83
in general payments reported to CMS, 2019-2025
21 companies · $648 in 2025
The $648 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.57 · 2022: $1,286 · 2023: $1,218 · 2024: $801 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612 · Education: $54.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.98 |
| Education | $54.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $591.53 | 2021-2024 | |
| Ucb, INC. | $526.13 | 2022-2025 | Briviact, Fintepla |
| Neurelis, INC. | $474.81 | 2022-2025 | Valtoco |
| Sk Life Science, INC. | $309.14 | 2022-2025 | |
| Abbvie INC. | $308.82 | 2022-2025 | |
| Csl Behring | $257.33 | 2022-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $252.32 | 2022-2023 | Austedo, Ajovy |
| Genzyme Corporation | $240.67 | 2022-2025 | |
| Eisai INC. | $184.96 | 2022-2025 | |
| Amgen INC. | $139.61 | 2024-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $123.61 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $120.42 | 2023 | Andexxa |
| Argenx US, INC. | $115.42 | 2024 | Vyvgart |
| Kyowa Kirin, INC. | $94.65 | 2023 | Nourianz |
| Depuy Synthes Sales INC. | $77.22 | 2025 | Embotrap |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $70.36 | 2024 | Panzyga |
| Ipsen Biopharmaceuticals, INC | $49.33 | 2023 | Dysport |
| Takeda Pharmaceuticals U.S.A., INC. | $33.88 | 2022 | |
| Biogen, INC. | $30.27 | 2024 | Vumerity, Tysabri |
| Sarepta Therapeutics, INC. | $29.91 | 2023 | Exondys 51 |
| Jazz Pharmaceuticals INC. | $22.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atif Ghaffar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.